Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study

Author:

Dergham Ana Paula12ORCID,Vaz de Paula Caroline Busatta1ORCID,Nagashima Seigo1ORCID,Olandoski Márcia1,de Noronha Lucia1ORCID,Sotomaior Vanessa Santos1

Affiliation:

1. Graduate Program in Health Sciences, School of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil

2. Neo Oncologia Núcleo de Estudos Oncológicos, Curitiba 80440-210, Brazil

Abstract

Advanced high-grade serous ovarian carcinoma is a serious malignant neoplasm with a late diagnosis and high mortality rate. Even when treated with standard therapy, such as surgery followed by carboplatin and paclitaxel chemotherapy, the prognosis remains unfavorable. Immunotherapy is a treatment alternative that requires further study. Therefore, we aimed to evaluate the expression of PD-1, PD-L1, CD8, MSI (MLH1, MSH2, MSH6, and PMS2), and p53 in the paraffin samples of high-grade serous ovarian carcinoma. A retrospective study of 28 southern Brazilian patients with advanced serous ovarian carcinoma (EC III or IV) was conducted between 2009 and 2020. The expression of these proteins was evaluated using immunohistochemistry, and the results were correlated with the patients’ clinicopathological data. At diagnosis, the mean age was 61 years, and the most common clinical stage (60%) was EC III. Among the cases, 84.6% exhibited p53 overexpression, 14.8% had MSI, 92.0% were sensitive to platinum, and more than 50.0% relapsed after treatment. Patients with MSI had a lower CD8/PD-1 ratio and more relapses (p = 0.03). In conclusion, analysis of immunotherapeutic markers in paraffin-embedded advanced serous ovarian carcinoma samples is feasible and may assist in prognosis.

Funder

Level 2 CNPq Research Productivity Scholar

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference44 articles.

1. Globocan (2021, March 08). The Global Cancer Observatory. Available online: https://gco.iarc.fr/.

2. (2021, March 08). INCA—Instituto Nacional do Câncer, Available online: www.inca.gov.br.

3. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

4. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N. Engl. J. Med.,2018

5. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer;Coleman;N. Engl. J. Med.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3